Vitamin D deficiency reduces the benefits of progesterone treatment after brain injury in aged rats

Neurobiology of Aging

Volumn 32, Issue 5, 2011, Pages 864-874

  Cekic, Milos ^a   Cutler, Sarah M ^a   VanLandingham, Jacob W ^a   Stein, Donald G ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

1,25 Dihydroxyvitamin D3; Aging; Inflammation; Progesterone; Traumatic brain injury; Vitamin D deficiency

Indexed keywords

CALCITRIOL; INTERLEUKIN 1BETA; INTERLEUKIN 6; PROGESTERONE; TRANSCRIPTION FACTOR RELA; TUMOR NECROSIS FACTOR ALPHA; VITAMIN D;

AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN CONTUSION; BRAIN LEVEL; BRAIN TISSUE; CONTROLLED STUDY; DISEASE EXACERBATION; ENCEPHALITIS; MALE; NONHUMAN; OPEN FIELD BEHAVIOR; PRIORITY JOURNAL; RAT; TRAUMATIC BRAIN INJURY; VITAMIN BLOOD LEVEL; VITAMIN D DEFICIENCY; VITAMIN SUPPLEMENTATION;

AGING; ANIMALS; BRAIN; BRAIN INJURIES; CYTOKINES; DISEASE MODELS, ANIMAL; MALE; PROGESTERONE; RATS; RATS, INBRED F344; VITAMIN D DEFICIENCY;

EID: 79954598164     PISSN: 01974580     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neurobiolaging.2009.04.017     Document Type: Article

References (93)

1. Asakura H., Aoshima K., Suga Y., Yamazaki M., Morishita E., Saito M., Miyamoto K., Nakao S. Beneficial effect of the active form of vitamin D3 against LPS-induced DIC but not against tissue-factor-induced DIC in rat models. Thromb. Haemost. 2001, 85:287-290.
2. Banerjee P., Chatterjee M. Antiproliferative role of vitamin D and its analogs-a brief overview. Mol. Cell. Biochem. 2003, 253:247-254.
3. Barrera D., Avila E., Hernandez G., Halhali A., Biruete B., Larrea F., Diaz L. Estradiol and progesterone synthesis in human placenta is stimulated by calcitriol. J. Steroid Biochem. Mol. Biol. 2007, 103:529-532.
4. Bauer B., Hartz A.M., Fricker G., Miller D.S. Pregnane X receptor up-regulation of P-glycoprotein expression and transport function at the blood-brain barrier. Mol. Pharmacol. 2004, 66:413-419.
5. Brewer L.D., Thibault V., Chen K.C., Langub M.C., Landfield P.W., Porter N.M. Vitamin D hormone confers neuroprotection in parallel with downregulation of L-type calcium channel expression in hippocampal neurons. J. Neurosci. 2001, 21:98-108.
6. Cantorna M.T., Mahon B.D. D-hormone and the immune system. J. Rheumatol. Suppl. 2005, 76:11-20.
7. CDC Traumatic Brain Injury (TBI): Incidence & Distribution 2004, Centers for Disease Control.
8. Charalampopoulos I., Alexaki V.I., Tsatsanis C., Minas V., Dermitzaki E., Lasaridis I., Vardouli L., Stournaras C., Margioris A.N., Castanas E., Gravanis A. Neurosteroids as endogenous inhibitors of neuronal cell apoptosis in aging. Ann. N.Y. Acad. Sci. 2006, 1088:139-152.
9. Chatfield S.M., Brand C., Ebeling P.R., Russell D.M. Vitamin D deficiency in general medical inpatients in summer and winter. Intern. Med. J. 2007, 37:377-382.
10. Chen K.B., Lin A.M., Chiu T.H. Systemic vitamin D3 attenuated oxidative injuries in the locus coeruleus of rat brain. Ann. N.Y. Acad. Sci. 2003, 993:313-324. (discussion 345-319).
11. Corino A., D'Amelio P., Gancia R., Del Rizzo P., Gabasio S., Limone P., Isaia G. Hypovitaminosis D in internal medicine inpatients. Calcif. Tissue Int. 2007, 80:76-80.
12. Cutler S.M., Cekic M., Miller D.M., Wali B., VanLandingham J.W., Stein D.G. Progesterone improves acute recovery after traumatic brain injury in the aged rat. J. Neurotrauma 2007, 24:1475-1486.
13. Diamond T.H., Ho K.W., Rohl P.G., Meerkin M. Annual intramuscular injection of a megadose of cholecalciferol for treatment of vitamin D deficiency: efficacy and safety data. Med. J. Aust. 2005, 183:10-12.
14. Djebaili M., Hoffman S.W., Stein D.G. Allopregnanolone and progesterone decrease cell death and cognitive deficits after a contusion of the rat pre-frontal cortex. Neuroscience 2004, 123:349-359.
15. Eelen G., Verlinden L., van Camp M., van Hummelen P., Marchal K., de Moor B., Mathieu C., Carmeliet G., Bouillon R., Verstuyf A. The effects of 1alpha 25-dihydroxyvitamin D3 on the expression of DNA replication genes. J. Bone Miner. Res. 2004, 19:133-146.
16. Elmadfa I., Meyer A.L. Body composition, changing physiological functions and nutrient requirements of the elderly. Ann. Nutr. Metab. 2008, 52(Suppl. 1):2-5.
17. Garcion E., Sindji L., Nataf S., Brachet P., Darcy F., Montero-Menei C.N. Treatment of experimental autoimmune encephalomyelitis in rat by 1,25-dihydroxyvitamin D3 leads to early effects within the central nervous system. Acta Neuropathol. (Berl.) 2003, 105:438-448.
18. Garcion E., Wion-Barbot N., Montero-Menei C.N., Berger F., Wion D. New clues about vitamin D functions in the nervous system. Trends Endocrinol. Metab. 2002, 13:100-105.
19. Gaugris S., Heaney R.P., Boonen S., Kurth H., Bentkover J.D., Sen S.S. Vitamin D inadequacy among post-menopausal women: a systematic review. QJM 2005, 98:667-676.
20. Gibson C.L., Gary L.J., Bath P.M., Murphy S.P. Progesterone for the treatment of experimental brain injury: a systematic review. Brain 2008, 131:318-328.
21. Giulietti A., Gysemans C., Stoffels K., van Etten E., Decallonne B., Overbergh L., Bouillon R., Mathieu C. Vitamin D deficiency in early life accelerates Type 1 diabetes in non-obese diabetic mice. Diabetologia 2004, 47:451-462.
22. Goss C.W., Hoffman S.W., Stein D.G. Behavioral effects and anatomic correlates after brain injury: a progesterone dose-response study. Pharmacol. Biochem. Behav. 2003, 76:231-242.
23. Grant W.B. Epidemiology of disease risks in relation to vitamin D insufficiency. Prog. Biophys. Mol. Biol. 2006, 92:65-79.
24. Grant W.B., Holick M.F. Benefits and requirements of vitamin D for optimal health: a review. Altern. Med. Rev. 2005, 10:94-111.
25. Grossman K.J., Stein D.G. Does endogenous progesterone promote recovery of chronic sensorimotor deficits following contusion to the forelimb representation of the sensorimotor cortex?. Behav. Brain Res. 2000, 116:141-148.
26. Gupta R., Dixon K.M., Deo S.S., Holliday C.J., Slater M., Halliday G.M., Reeve V.E., Mason R.S. Photoprotection by 1,25 dihydroxyvitamin D3 is associated with an increase in p53 and a decrease in nitric oxide products. J. Invest. Dermatol. 2007, 127:707-715.
27. Gurlek A., Pittelkow M.R., Kumar R. Modulation of growth factor/cytokine synthesis and signaling by 1alpha 25-dihydroxyvitamin D(3): implications in cell growth and differentiation. Endocr. Rev. 2002, 23:763-786.
28. Hayes C.E., Cantorna M.T., DeLuca H.F. Vitamin D and multiple sclerosis. Proc. Soc. Exp. Biol. Med. 1997, 216:21-27.
29. Hayes C.E., Nashold F.E., Spach K.M., Pedersen L.B. The immunological functions of the vitamin D endocrine system. Cell. Mol. Biol. (Noisy-le-grand) 2003, 49:277-300.
30. He J., Evans C.O., Hoffman S.W., Oyesiku N.M., Stein D.G. Progesterone and allopregnanolone reduce inflammatory cytokines after traumatic brain injury. Exp. Neurol. 2004, 189:404-412.
31. Heaney R.P. Functional indices of vitamin D status and ramifications of vitamin D deficiency. Am. J. Clin. Nutr. 2004, 80:1706S-1709S.
32. Holick M.F. Sunlight and vitamin D for bone health and prevention of autoimmune diseases, cancers, and cardiovascular disease. Am. J. Clin. Nutr. 2004, 80:1678S-1688S.
33. Holick M.F. The vitamin D epidemic and its health consequences. J. Nutr. 2005, 135:2739S-2748S.
34. Holick M.F. Vitamin D: important for prevention of osteoporosis, cardiovascular heart disease, type 1 diabetes, autoimmune diseases, and some cancers. South Med. J. 2005, 98:1024-1027.
35. Holick M.F., Chen T.C. Vitamin D deficiency: a worldwide problem with health consequences. Am. J. Clin. Nutr. 2008, 87:1080S-1086S.
36. Holick M.F., Siris E.S., Binkley N., Beard M.K., Khan A., Katzer J.T., Petruschke R.A., Chen E., de Papp A.E. Prevalence of Vitamin D inadequacy among postmenopausal North American women receiving osteoporosis therapy. J. Clin. Endocrinol. Metab. 2005, 90:3215-3224.
37. Kalueff A.V., Lou Y.R., Laaksi I., Tuohimaa P. Impaired motor performance in mice lacking neurosteroid vitamin D receptors. Brain Res. Bull. 2004, 64:25-29.
38. Kalueff A.V., Lou Y.R., Laaksi I., Tuohimaa P. Increased anxiety in mice lacking vitamin D receptor gene. Neuroreport 2004, 15:1271-1274.
39. Keel M., Trentz O. Pathophysiology of polytrauma. Injury 2005, 36:691-709.
40. Khazai N., Judd S.E., Tangpricha V. Calcium and vitamin D: skeletal and extraskeletal health. Curr. Rheumatol. Rep. 2008, 10:110-117.
41. Kutuzova G.D., Deluca H.F. Gene expression profiles in rat intestine identify pathways for 1,25-dihydroxyvitamin D(3) stimulated calcium absorption and clarify its immunomodulatory properties. Arch. Biochem. Biophys. 2004, 432:152-166.
42. Langmade S.J., Gale S.E., Frolov A., Mohri I., Suzuki K., Mellon S.H., Walkley S.U., Covey D.F., Schaffer J.E., Ory D.S. Pregnane X receptor (PXR) activation: a mechanism for neuroprotection in a mouse model of Niemann-Pick C disease. Proc. Natl. Acad. Sci. U.S.A. 2006, 103:13807-13812.
43. Larrosa M., Gratacos J., Vaqueiro M., Prat M., Campos F., Roque M. Prevalence of hypovitaminosis D in elderly institutionalized residents: influence of a substitutive treatment. Med. Clin. (Barc.) 2001, 117:611-614.
44. Li Y.C., Kong J., Wei M., Chen Z.F., Liu S.Q., Cao L.P. 1,25-Dihydroxyvitamin D(3) is a negative endocrine regulator of the rennin-angiotensin system. J. Clin. Invest. 2002, 110:229-238.
45. Lin A.M., Fan S.F., Yang D.M., Hsu L.L., Yang C.H. Zinc-induced apoptosis in substantia nigra of rat brain: neuroprotection by vitamin D3. Free Radic. Biol. Med. 2003, 34:1416-1425.
46. Lipsitz L.A. Physiological complexity, aging, and the path to frailty. Sci. Aging Knowledge Environ. 2004, 16.
47. Losem-Heinrichs E., Gorg B., Redecker C., Schleicher A., Witte O.W., Zilles K., Bidmon H.J. 1alpha 25-dihydroxy-vitamin D3 in combination with 17beta-estradiol lowers the cortical expression of heat shock protein-27 following experimentally induced focal cortical ischemia in rats. Arch. Biochem. Biophys. 2005, 439:70-79.
48. Lowe L.C., Guy M., Mansi J.L., Peckitt C., Bliss J., Wilson R.G., Colston K.W. Plasma 25-hydroxy vitamin D concentrations, vitamin D receptor genotype and breast cancer risk in a UK Caucasian population. Eur. J. Cancer 2005, 41:1164-1169.
49. MacFarlane G.D., Sackrison J.L., Body J.J., Ersfeld D.L., Fenske J.S., Miller A.B. Hypovitaminosis D in a normal, apparently healthy urban European population. J. Steroid Biochem. Mol. Biol. 2004, 89-90:621-622.
50. Markle-Reid M., Browne G. Conceptualizations of frailty in relation to older adults. J. Adv. Nurs. 2003, 44:58-68.
51. Martins D., Wolf M., Pan D., Zadshir A., Tareen N., Thadhani R., Felsenfeld A., Levine B., Mehrotra R., Norris K. Prevalence of cardiovascular risk factors and the serum levels of 25-hydroxyvitamin D in the United States: data from the Third National Health and Nutrition Examination Survey. Arch. Intern. Med. 2007, 167:1159-1165.
52. McCarty M.F. Secondary hyperparathyroidism promotes the acute phase response-a rationale for supplemental vitamin D in prevention of vascular events in the elderly. Med. Hypotheses 2005, 64:1022-1026.
53. Melamed M.L., Muntner P., Michos E.D., Uribarri J., Weber C., Sharma J., Raggi P. Serum 25-hydroxyvitamin D levels and the prevalence of peripheral arterial disease: results from NHANES 2001 to 2004. Arterioscler. Thromb. Vasc. Biol. 2008, 28:1179-1185.
54. Michos E.D., Melamed M.L. Vitamin D and cardiovascular disease risk. Curr. Opin. Clin. Nutr. Metab. Care 2008, 11:7-12.
55. Moore M., Piazza A., Nolan Y., Lynch M.A. Treatment with dexamethasone and vitamin D3 attenuates neuroinflammatory age-related changes in rat hippocampus. Synapse 2007, 61:851-861.
56. Mosenthal A.C., Lavery R.F., Addis M., Kaul S., Ross S., Marburger R., Deitch E.A., Livingston D.H. Isolated traumatic brain injury: age is an independent predictor of mortality and early outcome. J. Trauma 2002, 52:907-911.
57. Munger K.L., Zhang S.M., O'Reilly E., Hernan M.A., Olek M.J., Willett W.C., Ascherio A. Vitamin D intake and incidence of multiple sclerosis. Neurology 2004, 62:60-65.
58. Narayanan R., Allen M.R., Gaddy D., Bloomfield S.A., Smith C.L., Weigel N.L. Differential skeletal responses of hindlimb unloaded rats on a vitamin D-deficient diet to 1,25-dihydroxyvitamin D3 and its analog, seocalcitol (EB1089). Bone 2004, 35:134-143.
59. Offer H., Erez N., Zurer I., Tang X., Milyavsky M., Goldfinger N., Rotter V. The onset of p53-dependent DNA repair or apoptosis is determined by the level of accumulated damaged DNA. Carcinogenesis 2002, 23:1025-1032.
60. Onyszchuk G., He Y.Y., Berman N.E., Brooks W.M. Detrimental effects of aging on outcome from traumatic brain injury: a behavioral, magnetic resonance imaging, and histological study in mice. J. Neurotrauma 2008, 25:153-171.
61. Pascussi J.M., Robert A., Nguyen M., Walrant-Debray O., Garabedian M., Martin P., Pineau T., Saric J., Navarro F., Maurel P., Vilarem M.J. Possible involvement of pregnane X receptor-enhanced CYP24 expression in drug-induced osteomalacia. J. Clin. Invest. 2005, 115:177-186.
62. Peterlik M., Cross H.S. Vitamin D and calcium deficits predispose for multiple chronic diseases. Eur. J. Clin. Invest. 2005, 35:290-304.
63. Pettus E.H., Wright D.W., Stein D.G., Hoffman S.W. Progesterone treatment inhibits the inflammatory agents that accompany traumatic brain injury. Brain Res. 2005, 1049:112-119.
64. Pfeifer M., Begerow B., Minne H.W. Vitamin D and muscle function. Osteoporos. Int. 2002, 13:187-194.
65. Polek T.C., Stewart L.V., Ryu E.J., Cohen M.B., Allegretto E.A., Weigel N.L. p53 Is required for 1,25-dihydroxyvitamin D3-induced G0 arrest but is not required for G1 accumulation or apoptosis of LNCaP prostate cancer cells. Endocrinology 2003, 144:50-60.
66. Rajakumar K., Fernstrom J.D., Holick M.F., Janosky J.E., Greenspan S.L. Vitamin D status and response to Vitamin D(3) in obese vs. non-obese African American children. Obesity (Silver Spring) 2008, 16:90-95.
67. Rammos G., Tseke P., Ziakka S. Vitamin D, the renin-angiotensin system, and insulin resistance. Int. Urol. Nephrol. 2008.
68. Robsahm T.E., Tretli S., Dahlback A., Moan J. Vitamin D3 from sunlight may improve the prognosis of breast-, colon- and prostate cancer (Norway). Cancer Causes Control 2004, 15:149-158.
69. Rojanasathit S., Haddad J.G. Ontogeny and effect of vitamin D deprivation on rat serum 25-hydroxyvitamin D binding protein. Endocrinology 1977, 100:642-647.
70. Samina Riaz S., Tomlinson D.R. Pharmacological modulation of nerve growth factor synthesis: a mechanistic comparison of vitamin D receptor and beta(2)-adrenoceptor agonists. Brain Res. Mol. Brain Res. 2000, 85:179-188.
71. Sanchez B., Lopez-Martin E., Segura C., Labandeira-Garcia J.L., Perez-Fernandez R. 1,25-Dihydroxyvitamin D(3) increases striatal GDNF mRNA and protein expression in adult rats. Brain Res. Mol. Brain Res. 2002, 108:143-146.
72. Schumacher M., Guennoun R., Stein D.G., De Nicola A.F. Progesterone: therapeutic opportunities for neuroprotection and myelin repair. Pharmacol. Ther. 2007, 116:77-106.
73. Shinpo K., Kikuchi S., Sasaki H., Moriwaka F., Tashiro K. Effect of 1,25-dihydroxyvitamin D(3) on cultured mesencephalic dopaminergic neurons to the combined toxicity caused by l-buthionine sulfoximine and 1-methyl-4-phenylpyridine. J. Neurosci. Res. 2000, 62:374-382.
74. Singh M., Sumien N., Kyser C., Simpkins J.W. Estrogens and progesterone as neuroprotectants: what animal models teach us. Front. Biosci. 2008, 13:1083-1089.
75. Spach K.M., Hayes C.E. Vitamin D3 confers protection from autoimmune encephalomyelitis only in female mice. J. Immunol. 2005, 175:4119-4126.
76. Stein D.G. Progesterone exerts neuroprotective effects after brain injury. Brain Res. Rev. 2008, 57:386-397.
77. Stein D.G., Wright D.W., Kellermann A.L. Does progesterone have neuroprotective properties?. Ann. Emerg. Med. 2008, 51:164-172.
78. Tangpricha V., Turner A., Spina C., Decastro S., Chen T.C., Holick M.F. Tanning is associated with optimal vitamin D status (serum 25-hydroxyvitamin D concentration) and higher bone mineral density. Am. J. Clin. Nutr. 2004, 80:1645-1649.
79. Thien R., Baier K., Pietschmann P., Peterlik M., Willheim M. Interactions of 1 alpha 25-dihydroxyvitamin D3 with IL-12 and IL-4 on cytokine expression of human T lymphocytes. J. Allergy Clin. Immunol. 2005, 116:683-689.
80. Thomas M.K., Lloyd-Jones D.M., Thadhani R.I., Shaw A.C., Deraska D.J., Kitch B.T., Vamvakas E.C., Dick I.M., Prince R.L., Finkelstein J.S. Hypovitaminosis D in medical inpatients. N. Engl. J. Med. 1998, 338:777-783.
81. Topinkova E. Aging, disability and frailty. Ann. Nutr. Metab. 2008, 52(Suppl. 1):6-11.
82. VanLandingham J.W., Cekic M., Cutler S., Hoffman S.W., Stein D.G. Neurosteroids reduce inflammation after TBI through CD55 induction. Neurosci. Lett. 2007, 425:94-98.
83. Vieth R., Kimball S. Vitamin D in congestive heart failure. Am. J. Clin. Nutr. 2006, 83:731-732.
84. Wang J.Y., Wu J.N., Cherng T.L., Hoffer B.J., Chen H.H., Borlongan C.V., Wang Y. Vitamin D(3) attenuates 6-hydroxydopamine-induced neurotoxicity in rats. Brain Res. 2001, 904:67-75.
85. Wang T.J., Pencina M.J., Booth S.L., Jacques P.F., Ingelsson E., Lanier K., Benjamin E.J., D'Agostino R.B., Wolf M., Vasan R.S. Vitamin D deficiency and risk of cardiovascular disease. Circulation 2008, 117:503-511.
86. Wang Y., Chiang Y.H., Su T.P., Hayashi T., Morales M., Hoffer B.J., Lin S.Z. Vitamin D(3) attenuates cortical infarction induced by middle cerebral arterial ligation in rats. Neuropharmacology 2000, 39:873-880.
87. Wright D.W., Bauer M.E., Hoffman S.W., Stein D.G. Serum progesterone levels correlate with decreased cerebral edema after traumatic brain injury in male rats. J. Neurotrauma 2001, 18:901-909.
88. Wright D.W., Kellermann A.L., Hertzberg V.S., Clark P.L., Frankel M., Goldstein F.C., Salomone J.P., Dent L.L., Harris O.A., Ander D.S., Lowery D.W., Patel M.M., Denson D.D., Gordon A.B., Wald M.M., Gupta S., Hoffman S.W., Stein D.G. ProTECT: a randomized clinical trial of progesterone for acute traumatic brain injury. Ann. Emerg. Med. 2007, 402:e391-e392. 49, e391-e402.
89. Xiao G., Wei J., Yan W., Wang W., Lu Z. Improved outcomes from the administration of progesterone for patients with acute severe traumatic brain injury: a randomized controlled trial. Crit. Care 2008, 12:R61.
90. Xu Y., Hashizume T., Shuhart M.C., Davis C.L., Nelson W.L., Sakaki T., Kalhorn T.F., Watkins P.B., Schuetz E.G., Thummel K.E. Intestinal and hepatic CYP3A4 catalyze hydroxylation of 1alpha 25-dihydroxyvitamin D(3): implications for drug-induced osteomalacia. Mol. Pharmacol. 2006, 69:56-65.
91. Zasloff M. Fighting infections with vitamin D. Nat. Med. 2006, 12:388-390.
92. Zhu Y., Mahon B.D., Froicu M., Cantorna M.T. Calcium and 1 alpha 25-dihydroxyvitamin D3 target the TNF-alpha pathway to suppress experimental inflammatory bowel disease. Eur. J. Immunol. 2005, 35:217-224.
93. Zygun D. Non-neurological organ dysfunction in neurocritical care: impact on outcome and etiological considerations. Curr. Opin. Crit. Care 2005, 11:139-143.